You are here: Industry Insights > HNSCC

News List

Key unmet needs in HNSCC may be partly addressed by clinical development in next decade: GlobalData expresspharma
June 02, 2021
The next decade may see the introduction of personalised therapy options in locally advanced HNSCC settings along with identification of new druggable targets.
Adlai Nortye Announces First Patient Dosed in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic Head and Neck Squamous prnasia
April 15, 2021
Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the global phase III clinical trial (BURAN) at Shanghai Eastern Hospital Medical Center in China.
MitoImmune Received FDA Clearance of IND Application for MIT-001, a Novel Anti-Inflammatory/Anti-Necrotic Therapy for Oral Mucositis in CCRT patients with Head and Neck Cancer prnasia
April 06, 2021
MitoImmune Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for MIT-001, an innovative new drug candidate for the treatment of oral mucositis.
Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib americanpharmaceuticalreview
March 01, 2021
Kura Oncology announced its investigational drug, tipifarnib, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HRAS mutant head and ...
AZ’s Imfinzi fails to improve overall survival in head and neck cancer again pharmatimes
February 09, 2021
AstraZeneca’s Imfinzi has failed to improved overall survival (OS) in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) for the second time.
NICE recommends Keytruda (pembrolizumab) for treatment of HNSCC europeanpharmaceuticalreview
October 26, 2020
NICE has recommended pembrolizumab for the treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).
Vaccinex, Merck Collaborate on Keytruda Combo contractpharma
September 18, 2020
Vaccinex Inc., a clinical-stage biotechnology company, has entered into a clinical collaboration agreement with Merck through a subsidiary, to evaluate the combination of Vaccinex’s investigational SEMA4D inhibitor, pepinemab, and Merck’s anti-PD-1 ...
Kura Oncology Reports Data from Tipifarnib Trial in Head and Neck Squamous Cell Carcinoma americanpharmaceuticalreview
June 08, 2020
Kura Oncology announced updated clinical outcome data from its RUN-HN study, a Phase 2 open-label, single-arm trial of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) whose disease had progressed after prior therapy.
QBiotics Announces First Patient Dosed in its Phase I/II Clinical Trial of Tigilanol Tiglate for Head and Neck Cancer En-CPhI.CN
December 03, 2019
QBiotics Group Limited (QGL), a life sciences company developing novel anticancer and wound healing pharmaceuticals ...
FDA Approves Pembrolizumab for First-Line Treatment of HNSCC americanpharmaceuticalreview
June 13, 2019
The Food and Drug Administration (FDA) approved pembrolizumab (KEYTRUDA, Merck) for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC).

Previous page 1 2 Next page